Aytu BioPharma, Inc. AYTU

2.28 (0.03) (1.30%) as of 25 Sep
Market cap
$25.1M
P/E
0.0×
Jun '17 Jun '18 Jun '19 Jun '20 Jun '21 Jun '22 Jun '23 Jun '24 Jun '25 Jun '26
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
33.70 0.94 2.05 2.32 1.28 0.21 0.05 0.24 0.21 0.46
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.19
P/Operating CF
(33.21) (0.76) (4.31) (8.27) (13.37) (2.86) 0.57 (20.03) 4.88 6.01
P/B ratio
27.14 0.26 2.11 0.68 0.61 0.46 0.14 0.57 0.72 0.75
EV/Sales
33.43 (1.00) 1.20 1.10 0.90 0.20 (0.01) 0.17 0.07 0.30
EV/EBITDA
0.00 0.21 0.00 0.00 0.00 0.00 0.17 1.90 0.00 0.00
EV/FCF
(7.72) 0.22 (0.61) (0.76) (1.47) (0.45) 0.07 (0.97) (3.04) 5.32
Current Ratio
0.84 2.79 2.87 2.62 0.96 0.93 1.03 0.99 1.26 1.13
Net Debt/EBITDA
0.06 0.42 0.80 2.27 0.68 0.05 0.86 (0.85) 3.90 2.17
Debt/Equity
0.00 0.00 0.00 0.15 0.18 0.41 0.42 0.55 1.15 0.48
ROE
(319.60%) (116.94%) (264.55%) (26.68%) (50.12%) (119.62%) (40.76%) (47.24%) (58.10%) (52.55%)
ROA
(114.43%) (56.51%) (97.28%) (14.49%) (27.83%) (53.95%) (12.44%) (12.45%) (11.20%) (12.44%)
ROIC
(402.85%) (195.07%) 0.00% (21.59%) (32.72%) (159.24%) (32.58%) (4.35%) (49.77%) (19.99%)
Return on Tangible Assets
(34,416.36%) (161.86%) (264.34%) (29.03%) (6,227.46%) 7,310.42% (439.57%) (4,450.56%) (81.47%) (190.36%)
Average Days of Receivables
59.82 57.72 86.80 74.41 156.70 81.98 98.34 131.74 171.31 144.42
Earnings Yield
(418.31%) (295.13%) (233.33%) (20.88%) (70.50%) (552.17%) (309.28%) (100.35%) (87.16%) (53.30%)
Free Cash Flow Yield
(12.84%) (479.99%) (96.10%) (62.44%) (47.68%) (211.30%) (358.72%) (71.33%) (10.93%) 12.21%
Free Cash Flow per Share
(6,061.43) (4,974.24) (369.01) (151.43) (33.80) (19.61) (1.54) (0.31) (0.24) 0.26
Book value per Share
1,739.04 4,068.03 181.74 420.42 164.28 30.14 11.78 5.00 3.02 2.86
Free Cash Flow
(13.94) (16.41) (14.39) (34.22) (28.30) (28.82) (5.13) (1.72) (1.50) 3.25
EV/EBIT
0.00 0.19 0.00 0.00 0.00 0.00 0.08 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 24 Sep 2026